Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Express Scripts
Colorcon
McKesson
Moodys

Last Updated: June 27, 2022

IMODIUM MULTI-SYMPTOM RELIEF Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Imodium Multi-symptom Relief patents expire, and when can generic versions of Imodium Multi-symptom Relief launch?

Imodium Multi-symptom Relief is a drug marketed by J And J Consumer Inc and is included in two NDAs.

The generic ingredient in IMODIUM MULTI-SYMPTOM RELIEF is loperamide hydrochloride; simethicone. There are eleven drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the loperamide hydrochloride; simethicone profile page.

Summary for IMODIUM MULTI-SYMPTOM RELIEF
Drug patent expirations by year for IMODIUM MULTI-SYMPTOM RELIEF
Recent Clinical Trials for IMODIUM MULTI-SYMPTOM RELIEF

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Naia PharmaceuticalsPhase 1/Phase 2
9 Meters Biopharma, Inc.Phase 1/Phase 2
McNeil ABPhase 1

See all IMODIUM MULTI-SYMPTOM RELIEF clinical trials

Pharmacology for IMODIUM MULTI-SYMPTOM RELIEF
Drug ClassOpioid Agonist
Mechanism of Action Opioid Agonists
Physiological Effect Skin Barrier Activity
Paragraph IV (Patent) Challenges for IMODIUM MULTI-SYMPTOM RELIEF
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
IMODIUM MULTI-SYMPTOM RELIEF Tablets loperamide hydrochloride; simethicone 2 mg/125 mg 021140 2004-12-29

US Patents and Regulatory Information for IMODIUM MULTI-SYMPTOM RELIEF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
J And J Consumer Inc IMODIUM MULTI-SYMPTOM RELIEF loperamide hydrochloride; simethicone TABLET, CHEWABLE;ORAL 020606-001 Jun 26, 1996 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
J And J Consumer Inc IMODIUM MULTI-SYMPTOM RELIEF loperamide hydrochloride; simethicone TABLET;ORAL 021140-001 Nov 30, 2000 OTC Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for IMODIUM MULTI-SYMPTOM RELIEF

International Patents for IMODIUM MULTI-SYMPTOM RELIEF

See the table below for patents covering IMODIUM MULTI-SYMPTOM RELIEF around the world.

Country Patent Number Title Estimated Expiration
Australia 634833 See Plans and Pricing
Poland 189988 See Plans and Pricing
Czech Republic 294084 Sypká granulovaná kompoziceŹ způsob její výroby a protipěnivá orální pevná dávková forma simethikonu (Free flowing granular composition, process for its preparation and antifoam simethicone oral solid dosage form) See Plans and Pricing
Brazil 1100507 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for IMODIUM MULTI-SYMPTOM RELIEF

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0428296 99C0029 Belgium See Plans and Pricing PRODUCT NAME: LOPERAMIDUM HYDROCHOLORIDUM SEMITHICONUM; NATL. REGISTRATION NO/DATE: 2 IS 145 F3 19990201; FIRST REGISTRATION: GB PL 00242/0314 19970923
0428296 SPC/GB98/013 United Kingdom See Plans and Pricing PRODUCT NAME: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE; REGISTERED: UK 00242/0314 19970923
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
McKinsey
Medtronic
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.